HJLI News and Press, Hancock Jaffe Laboratories Inc. From 08/03/21

Hancock Jaffe Laboratories (NASDAQ:HJLI) soars 39.6% premarket in reaction to the announcement that the FDA has granted Breakthrough Device Designation status to the VenoValve, the Company's lead product, which is currently set to begin its U.S. pivotal trial. The designation, akin ...

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE U.S. pivotal trial for VenoValve - VenoValve is a potential treatment for approx...

The following slide deck was published by Hancock Jaffe Laboratories, Inc. in conjunction with this event. For further details see: Hancock Jaffe Laboratories <<HJLI>> presents at HealthVirtual Conference - slideshow

Live webcast on Tuesday, July 13 th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman,...

IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve ® stud...

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company...

Hancock Jaffe Laboratories shares up ([[HJLI]] +4.3%) after the U.S. FDA approved the company's Investigational Device Exemption ((IDE)) application to begin the U.S. pivotal trial for the VenoValve.The VenoValve is an implantable valve designed to restore proper direction...

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption ...

IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Admin...

Company Receives Notice of Allowance from U.S. Patent and Trademark Office IRVINE, CA / ACCESSWIRE / February 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a...